.Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BX07_Vosoritide.Vosoritide .Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BX07_Vosoritide.Vosoritide| name: | Vosoritide | |
| ATC code: | M05BX07 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 15 | mg |
| volume of distribution: | 8.4 | L |
| clearance: | 24.7 | L/h |
| other parameters in model implementation | ||
Vosoritide is a recombinant human C-type natriuretic peptide (CNP) analogue indicated for the treatment of achondroplasia in patients who are aged 2 years and older with open epiphyses. It is approved for use in several regions, including the US and EU. Vosoritide acts as a growth modulator by binding to natriuretic peptide receptor NPR-B (NPR2), stimulating endochondral bone growth.
Pharmacokinetic parameters reported in pediatric subjects (age 5-14 years) with achondroplasia after daily subcutaneous administration of vosoritide. The model assumes a one-compartment disposition.